[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Patargias et al., 2006 - Google Patents

Protein− protein interactions: modeling the hepatitis C virus ion channel p7

Patargias et al., 2006

View PDF
Document ID
9449861350584867135
Author
Patargias G
Zitzmann N
Dwek R
Fischer W
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

The p7 protein is a small ion-channel-forming membrane polypeptide encoded by the hepatitis C virus which consists of two transmembrane α-helices, TM1 and TM2, and can be blocked by long-alkyl-chain iminosugar derivatives. The length of TM1 and TM2 was …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/16—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/70—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds
    • G06F19/706—Chemoinformatics, i.e. data processing methods or systems for the retrieval, analysis, visualisation, or storage of physicochemical or structural data of chemical compounds for drug design with the emphasis on a therapeutic agent, e.g. ligand-biological target interactions, pharmacophore generation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/12—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for modelling or simulation in systems biology, e.g. probabilistic or dynamic models, gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/22—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or SNP [Single-Nucleotide Polymorphism] discovery or sequence alignment

Similar Documents

Publication Publication Date Title
Patargias et al. Protein− protein interactions: modeling the hepatitis C virus ion channel p7
Chowdhury et al. Antiviral peptides as promising therapeutics against SARS-CoV-2
Toft-Bertelsen et al. Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro
Amendola et al. Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening
Panda et al. ACE-2-derived biomimetic peptides for the inhibition of spike protein of SARS-CoV-2
Llanos et al. Strengths and weaknesses of docking simulations in the SARS-CoV-2 era: the main protease (Mpro) case study
Kneller et al. Structural, electronic, and electrostatic determinants for inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease
Cook et al. Three-dimensional structure and interaction studies of hepatitis C virus p7 in 1, 2-dihexanoyl-sn-glycero-3-phosphocholine by solution nuclear magnetic resonance
Wang et al. Supramolecular organization of SARS-CoV and SARS-CoV-2 virions revealed by coarse-grained models of intact virus envelopes
Gupta et al. Structure-based virtual screening and biochemical validation to discover a potential inhibitor of the SARS-CoV-2 main protease
Mukherjee et al. Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies
Cross et al. Sequence characterization and molecular modeling of clinically relevant variants of the SARS-CoV-2 main protease
Barroso da Silva et al. Electrostatic features for the receptor binding domain of SARS-COV-2 wildtype and its variants. Compass to the severity of the future variants with the charge-rule
Cong et al. Anchor-locker binding mechanism of the coronavirus spike protein to human ACE2: insights from computational analysis
Freitas et al. Shedding light on the inhibitory mechanisms of SARS-CoV-1/CoV-2 spike proteins by ACE2-designed peptides
Wubben et al. The role of protein disorder in nuclear transport and in its subversion by viruses
Borkotoky et al. Computational insight into the mechanism of SARS-CoV-2 membrane fusion
Coderc de Lacam et al. When the dust has settled: calculation of binding affinities from first principles for SARS-CoV-2 variants with quantitative accuracy
Manandhar et al. Discovery of novel small-molecule inhibitors of SARS-CoV-2 main protease as potential leads for COVID-19 treatment
de Campos et al. Targeting SARS-CoV-2 receptor binding domain with stapled peptides: an in silico study
Wang et al. The Inhibition of SARS-CoV-2 3CL Mpro by graphene and its derivatives from molecular dynamics simulations
Pourmand et al. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region
Kruger et al. Assembly of viral membrane proteins
Mottin et al. Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika
Bellows et al. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework